Stock comparison
Alnylam Pharmaceuticals
ALNY$35.71BHealthcare Market cap, Sector
SANOFI CONS HEALTHC IND L
SANOFICONR.NS$105.34BHealthcare Market cap, Sector
Overall winner
SANOFI CONS HEALTHC IND L
ALNY 16 SANOFICONR.NS
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
ALNY1wins
6winsSANOFICONR.NS
52D
B78
76B
A89
70B
B83
79B
B77
59D
A91
70B
A86
70B
A85
Side-by-side metrics
| Metric | ALNY | SANOFICONR.NS |
|---|---|---|
| Market cap | $35.71B | $105.34B Winner |
| P/E (TTM) | 68.1x | 44.2x Winner |
| EV/EBIT | 77.8x | 31.8x Winner |
| ROIC (TTM) | 19.66% | 59.15% Winner |
| Gross margin | Winner: 80.89% | 68.13% |
| Net margin | 13.46% | 27.35% Winner |
| Revenue CAGR 5y | Winner: 44.82% | 27.01% |
| EPS CAGR 5y | - | 20.67% |
| Debt / Equity | 1.2x | 0.1x Winner |
| Dividend yield | 0.0% | - |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALNY leads on
- Revenue CAGR 5y44.82%vs 27.01%+40%
- Gross margin80.89%vs 68.13%+16%
SANOFICONR.NS leads on
- Debt / Equity0.1xvs 1.2x+95%
- ROIC (TTM)59.15%vs 19.66%+67%
- Market cap$105.34Bvs $35.71B+66%
- EV/EBIT31.8xvs 77.8x+59%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.